Quantcast

onPoint Oncology Announces Newest Team Addition: Rhoda Dunn

January 14, 2013

Rhoda Dunn will be taking on the role of Principal. She brings over 15 years of synergistic expertise to onPoint Oncology.

Hudson, OH (PRWEB) January 14, 2013

onPoint Oncology is pleased to announce that Rhoda Dunn is the company´s newest Principal. Ms. Dunn will focus on her core areas of synergistic expertise: coverage, reimbursement, and patient access. For over 13 years, Ms. Dunn has led numerous client engagements to assess the impact of government policy, pricing and reimbursement, and payer utilization management on the adoption and utilization of cancer therapeutics. She has also delivered numerous projects that have supported go/no-go decisions for pipeline compounds, such as disease state opportunity and reimbursement assessments. Besides extensive experience with many disease states, Ms. Dunn has become a domain expert on the treatment of advanced prostate cancer.

Prior to joining onPoint Oncology, Ms. Dunn edited and authored a variety of reports, including the 2009 edition of Oncology Market Access Europe and the 2011 and 2012 editions of Oncology Market Access US for her previous employer, Kantar Health.

Ms. Dunn began her career in medical publishing, where she spent 5 years garnering in-depth content development and publishing experience. She then applied this knowledge to medical education before focusing her efforts on marketing for the past 15 years.

Ms. Dunn earned a B.A. in English from the University of California, Davis and completed extensive studies in biochemistry and microeconomics.

onPoint Oncology LLC, founded in 2008, provides claims data analytics, direct to physician marketing tools, provider/company reimbursement strategy, and market research offerings focused on the Oncology product and provider markets. onPoint´s clients are companies and clinics in the cancer treatment and diagnostic areas.

For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2013/1/prweb10312201.htm


Source: prweb



comments powered by Disqus